Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51

Benzinga · 20h ago
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.